News | May 17, 2024
Cresset opens new new India HQ in Bengaluru to tap potential of APAC market
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
A significant proportion of healthcare professionals still tend to favor branded drugs
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Application based on results from the TROPION-Breast01 Phase III trial
Subscribe To Our Newsletter & Stay Updated
